Isoray (ISR)

Executive Summary

Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. More Details


Earnings are forecast to grow 68.82% per year

Earnings have grown 2.8% per year over the past 5 years

Risk Analysis

Has less than 1 year of cash runway

Volatile share price over the past 3 months

Shareholders have been diluted in the past year

Does not have a meaningful market cap ($32M)

Snowflake Analysis

High growth potential with adequate balance sheet.

Similar Companies

Search for a company to compare.